NASDAQ$ALKS
Alkermes plc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Alkermes reported strong first-quarter financial results driven by proprietary product net sales and disciplined cost management.
Alkermes plc reported first-quarter 2023 financial results, with total revenues of $287.6 million. The company saw strong performance in its proprietary product portfolio, with a 25% increase in net sales year-over-year. Alkermes is reiterating its financial expectations for 2023 and is progressing with the planned separation of its oncology business.
- First Quarter Revenues of $287.6 Million Reflect Strong Performance of Proprietary Product Portfolio.
- GAAP Loss per Share of $0.25 and Basic and Diluted Non-GAAP Earnings per Share of $0.01.
- Planned Separation of Oncology Business Expected to be Completed in Second Half of 2023.
- Financial Expectations for 2023 Reiterated.
Headline financials
Revenue & EPS history
Alkermes · Revenue · Quarterly
$288M
Revenue by segment
Alkermes · $215M total across 3 segments · Q1 2023
- VIVITROL$96.7M+13.9%45.0%
- ARISTADA$80.1M+10.5%37.3%
- LYBALVI$38M+173.4%17.7%
Forward guidance
Alkermes reiterates its financial expectations for 2023, as set forth in its press release dated Feb. 16, 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
-0.6%
Avg return
Earnings day
-0.0%
Avg return
5 days after
-0.5%
Avg return
30 days after
45%
27 / 60 earnings
Positive
+16.6%
Q4 2017
Best reaction
-14.8%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.2% | +2.5% | +27.0% | |
| Q4 2025 | -6.6% | -9.4% | -12.0% | |
| Q3 2025 | +3.9% | +3.3% | +0.0% | |
| Q1 2025 | +6.3% | +5.5% | +6.4% | |
| Q4 2024 | +4.8% | +12.3% | +6.5% | |
| Q3 2024 | -6.3% | -5.1% | +3.3% | |
| Q2 2024 | +12.2% | +11.7% | +11.8% | |
| Q1 2024 | -2.8% | -1.8% | -4.6% | |
| Q4 2023 | +15.0% | +8.6% | +2.7% | |
| Q3 2023 | -2.4% | -4.0% | -3.7% | |
| Q2 2023 | -1.8% | -5.1% | -11.9% | |
| Q1 2023 | -7.1% | -6.1% | -3.9% | |
| Q4 2022 | +4.0% | +2.9% | -3.6% | |
| Q3 2022 | +3.8% | +0.3% | +12.2% | |
| Q2 2022 | -9.7% | -14.4% | -16.5% | |
| Q1 2022 | +9.8% | +6.4% | +12.5% | |
| Q4 2021 | +8.8% | +7.6% | +12.1% | |
| Q3 2021 | -8.2% | -5.0% | -28.7% | |
| Q2 2021 | +5.9% | +11.6% | +28.9% | |
| Q1 2021 | -3.2% | -1.6% | +0.8% | |
| Q4 2020 | -11.8% | -13.7% | -15.3% | |
| Q3 2020 | +5.6% | +5.9% | +20.2% | |
| Q2 2020 | -8.8% | -7.4% | -19.0% | |
| Q1 2020 | -14.8% | -14.7% | +1.6% | |
| Q4 2019 | -7.0% | -7.8% | -15.5% | |
| Q3 2019 | +5.7% | +6.0% | +13.9% | |
| Q2 2019 | -10.2% | +1.2% | -12.3% | |
| Q1 2019 | -12.2% | -12.7% | -31.1% | |
| Q4 2018 | -1.2% | +3.6% | +3.3% | |
| Q3 2018 | +3.0% | +6.5% | -11.6% | |
| Q2 2018 | -0.1% | -0.3% | +2.0% | |
| Q1 2018 | +1.5% | +1.4% | +3.9% | |
| Q4 2017 | +16.6% | +23.0% | +12.0% | |
| Q3 2017 | +0.7% | -1.5% | +3.2% | |
| Q2 2017 | -4.1% | -5.4% | -12.4% | |
| Q1 2017 | +2.0% | +2.4% | +1.0% | |
| Q4 2016 | -2.9% | -4.6% | +3.7% | |
| Q3 2016 | -1.4% | +4.0% | +8.4% | |
| Q2 2016 | -3.6% | -6.0% | -14.1% | |
| Q1 2016 | -2.0% | — | — | |
| Q4 2015 | -1.4% | — | — | |
| Q3 2015 | +7.6% | — | — | |
| Q2 2015 | +2.4% | — | — | |
| Q1 2015 | +3.1% | — | — | |
| Q4 2014 | -3.4% | — | — | |
| Q3 2014 | +7.7% | — | — | |
| Q2 2014 | -7.2% | — | — | |
| Q1 2014 | +3.2% | — | — | |
| Q4 2013 | -7.7% | — | — | |
| Q3 2013 | -3.7% | — | — | |
| Q2 2013 | +3.5% | — | — | |
| Q1 2013 | +3.9% | — | — | |
| Q4 2010 | -1.0% | — | — | |
| Q4 2012 | -9.9% | — | — | |
| Q3 2012 | +2.2% | — | — | |
| Q3 2011 | +2.2% | — | — | |
| Q2 2011 | -7.7% | — | — | |
| Q2 2012 | -7.7% | — | — | |
| Q4 2011 | -7.7% | — | — | |
| Q2 2010 | -3.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro